BRANFORD, Conn.--(BUSINESS WIRE)--Affomix, the pioneer in digital proteomic reagents for next generation molecular assays and the leader in automated, high-throughput monoclonal antibody selection technology, today announced a collaboration with the internationally recognized University of Montreal Pharmacogenomics Centre (PGx Centre) and the Montreal Heart Institute.
